+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Vaccine for Children Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Respiratory Syncytial Virus Vaccine for Children Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Respiratory Syncytial Virus Vaccine for Children Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6081999
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The global pursuit of an effective respiratory syncytial virus (RSV) vaccine for children has reached a critical juncture as recent scientific breakthroughs converge with evolving public health priorities. RSV remains a leading cause of lower respiratory tract infections in infants and young children, driving significant morbidity and straining healthcare resources worldwide. This executive summary offers an informed gateway into the complexities of the pediatric RSV vaccine market, highlighting the latest clinical developments, regulatory momentum, and stakeholder interests. By synthesizing current landscape drivers and barriers, this introduction lays the foundation for a nuanced exploration of transformative trends, geopolitical influences, granular market segmentation, and strategic imperatives for manufacturers and policymakers alike. As the race to deliver safe, effective, and accessible RSV immunization intensifies, understanding the multifaceted dynamics at play will be essential for guiding investment decisions and optimizing public health outcomes across diverse pediatric populations.

Transformative Shifts Redefining the RSV Vaccine Ecosystem

Over the past two years, several paradigm-shifting developments have reshaped the RSV vaccine ecosystem for young children. First, advances in antigen design and adjuvant technology have enabled the development of subunit and peptide-based vaccines capable of eliciting durable humoral and cellular immunity. Simultaneously, next-generation monoclonal antibodies with extended half-lives and enhanced Fc receptor engagement offer new prophylactic options for high-risk infants. In parallel, intranasal live attenuated formulations are progressing through late-stage trials, promising needle-free delivery and mucosal immunity. These scientific innovations coincide with progressive regulatory frameworks that prioritize pediatric populations, accelerating review pathways and enabling conditional authorizations. Moreover, digital health platforms and telemedicine integration are facilitating at-home administration and remote monitoring, reducing burden on hospital systems. Finally, growing collaboration between biotech firms, big pharmaceutical players, and public health agencies has fostered risk-sharing models and expanded access initiatives in underserved regions. Together, these transformative shifts underscore the emergence of a dynamic, patient-centric market poised to redefine RSV prevention strategies for children.

Assessing the 2025 U.S. Tariff Effects on the RSV Vaccine Market

In 2025, newly imposed U.S. tariffs on critical raw materials and bioprocessing equipment are exerting upward pressure on production costs for vaccine developers. Steel tariffs have driven up the price of stainless steel bioreactors, while duties on single-use plastics and chromatography resins have escalated consumable expenses. These increased input costs are reverberating through the supply chain, leading to higher wholesale acquisition costs and potential reimbursement challenges. At the same time, import restrictions on key reagents necessitate the qualification of alternative suppliers, introducing validation delays and regulatory hurdles. Smaller biotech firms with limited sourcing flexibility may face production bottlenecks, whereas larger manufacturers are leveraging diversified procurement strategies to mitigate impact. Ultimately, the tariff environment is prompting sponsors to reevaluate manufacturing footprints, consider nearshoring initiatives, and explore toll-manufacturing partnerships. Stakeholders must stay vigilant to evolving trade policies, as tariff-related cost inflation could influence pricing negotiations with payers and shape the ultimate accessibility of pediatric RSV vaccines.

Integrative Insights from Comprehensive Segmentation Analysis

A nuanced assessment of the pediatric RSV vaccine market requires detailed segmentation across age demographics, vaccine modalities, distribution channels, manufacturer types, and mechanisms of action. When considering age, infants from birth to six months are subdivided into full-term and premature cohorts, each presenting distinct immunological profiles that influence vaccine candidate selection and dosing regimens. The six-to-twelve-month bracket further differentiates between healthy infants and those with compromised immunity, while the one-to-five-year group distinguishes between children with asthma and their healthy peers, guiding targeted prophylactic strategies. In terms of vaccine technology, live attenuated options deployed intramuscularly or via intranasal spray are juxtaposed with monoclonal antibodies-ranging from first-generation Palivizumab to novel, longer-acting constructs-and next-generation subunit platforms, which encompass both peptide and protein-based formulations. Distribution varies across hospital pharmacies in private and public settings, online providers through direct sales or third-party e-commerce, and retail pharmacies encompassing independent and supermarket outlets, each channel offering unique reach and logistical considerations. Market participants span global pharmaceutical incumbents, emerging biotech innovators, and generic drug makers, with established RSV leaders and potential entrants collaborating across licensing and co-development models. Finally, the interplay between prophylactic vaccines, preventive antibodies, and therapeutic interventions underscores the evolving role of both preemptive and post-exposure immunization within comprehensive pediatric care pathways.

Regional Dynamics Shaping RSV Vaccine Adoption Trends

Regional dynamics are shaping the uptake and distribution of RSV vaccines across the Americas, EMEA, and Asia-Pacific. In the Americas, robust pediatric immunization programs and favorable reimbursement frameworks support early adoption, though disparities in rural areas highlight the need for expanded cold-chain infrastructure. Across Europe, the Middle East and Africa, policy fragmentation presents both challenges and opportunities, as national immunization committees navigate diverse epidemiological burdens and budget constraints; advanced economies are prioritizing novel monoclonal antibodies, while emerging markets focus on cost-effective subunit vaccines. In the Asia-Pacific region, high birth cohorts coupled with accelerating healthcare investment are driving demand, and governments are forging public-private partnerships to bolster local manufacturing capacity. Meanwhile, regulatory harmonization initiatives, such as mutual recognition agreements and reliance pathways, are expediting approvals for global vaccine candidates. Understanding these regional nuances is vital for tailoring commercialization strategies, optimizing distribution logistics, and aligning pricing models with local healthcare priorities.

Strategic Profiles and Innovations from Key Market Players

Key industry players are deploying differentiated strategies to capture value and extend market share in the pediatric RSV domain. Global conglomerates such as Pfizer and Merck are leveraging their extensive clinical-development platforms to advance both subunit and monoclonal antibody candidates, while Moderna and Novavax are translating their mRNA and recombinant nanoparticle expertise into accelerated RSV programs. AstraZeneca, through its MedImmune arm, continues to refine live attenuated and vectored platforms, drawing on established pediatric virology capabilities. Meanwhile, GlaxoSmithKline and Sanofi are intensifying partnerships with biotech firms to co-develop prophylactic vaccines tailored for high-risk infants. Innovative startups like ReViral and BiondVax are pioneering peptide-based immunogens and pan-respiratory virus formulations, seeking to disrupt traditional paradigms. Generic drug manufacturers and Johnson Matthey Fine Chemicals are enhancing their role in toll-manufacturing and large-scale production of monoclonal antibodies. Across the board, collaborative licensing agreements, real-world evidence generation, and differentiated go-to-market models underscore a competitive yet cooperative landscape. These collective efforts reflect a commitment to delivering safe, efficacious, and accessible pediatric RSV interventions at scale.

Actionable Recommendations to Drive Competitive Advantage

Industry leaders must adopt a multipronged approach to secure competitive advantage in the evolving pediatric RSV vaccine arena. First, diversifying manufacturing footprints through strategic partnerships and contract development organizations will mitigate supply chain risks exacerbated by tariffs. Second, investing in real-world studies that demonstrate long-term safety and health-economic benefits will strengthen value propositions with payers and immunization committees. Third, leveraging digital channels to streamline vaccine delivery-such as at-home administration kits integrated with telehealth support-will enhance uptake and patient adherence. Fourth, forging cross-sector alliances with maternal and infant health stakeholders will expand education campaigns and optimize community outreach. Fifth, prioritizing pipeline diversification across prophylactic and therapeutic modalities ensures resilience amid shifting regulatory and epidemiological trends. By implementing these tactics, organizations can navigate geopolitical headwinds, differentiate product portfolios, and drive sustainable growth in pediatric RSV prevention.

Concluding Perspectives on the Future of Pediatric RSV Vaccines

The pediatric RSV vaccine sector stands at the threshold of transformative impact, blending cutting-edge science with strategic commercialization imperatives. As advanced modalities progress toward licensure and novel distribution models gain traction, stakeholders must maintain agility in adapting to trade policy fluctuations and regional healthcare priorities. The insights presented here-spanning segmentation nuances, geopolitical influences, and competitive landscapes-underscore the critical importance of an integrated market approach that balances innovation with access. Looking ahead, sustained collaboration between manufacturers, healthcare providers, and regulatory bodies will be key to delivering optimized immunization strategies that protect the most vulnerable children. Armed with these insights, decision-makers are well-positioned to steer their organizations toward meaningful contributions in the global fight against RSV.

Market Segmentation & Coverage

This research report categorizes the Respiratory Syncytial Virus Vaccine for Children Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • 0 to 6 Months
    • Full-term Infants
    • Premature Infants
  • 1 to 5 Years
    • Children with Asthma
    • Healthy Children
  • 6 to 12 Months
    • Healthy Children
    • Immunocompromised Children
  • Live Attenuated Vaccine
    • Intramuscular Administration
    • Intranasal Administration
  • Monoclonal Antibody
    • Newer Generation Antibodies
    • Palivizumab
  • Subunit Vaccine
    • Peptide-based Vaccine
    • Protein-based Vaccine
  • Hospital Pharmacies
    • Private Hospitals
    • Public Hospitals
  • Online Providers
    • Direct Sale Websites
    • E-commerce Platforms
  • Retail Pharmacies
    • Independent Pharmacies
    • Supermarket Pharmacies
  • Big Pharmaceutical Companies
    • Established RSV Vaccines Makers
    • Potential Entrants in RSV Market
  • Biotech Firms
    • Established Biotech Firms
    • Start-ups
  • Generic Drug Manufacturers
    • International Players
    • Local Players
  • Prophylactic
    • Preventive Antibodies
    • Preventive Vaccines
  • Therapeutic
    • Therapeutic Monoclonal Antibodies
    • Therapeutic Vaccines

This research report categorizes the Respiratory Syncytial Virus Vaccine for Children Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Respiratory Syncytial Virus Vaccine for Children Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • BiondVax Pharmaceuticals Ltd.
  • BioPharms Inc.
  • Clarus Therapeutics, Inc.
  • GlaxoSmithKline plc
  • GSK Biologicals SA
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Johnson Matthey Fine Chemicals
  • MedImmune, LLC (AstraZeneca)
  • Merck & Co., Inc.
  • Moderna Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • ReViral Ltd.
  • Sanofi S.A.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Syncytial Virus Vaccine for Children Market, by Age Group
8.1. Introduction
8.2. 0 to 6 Months
8.2.1. Full-term Infants
8.2.2. Premature Infants
8.3. 1 to 5 Years
8.3.1. Children with Asthma
8.3.2. Healthy Children
8.4. 6 to 12 Months
8.4.1. Healthy Children
8.4.2. Immunocompromised Children
9. Respiratory Syncytial Virus Vaccine for Children Market, by Type of Vaccine
9.1. Introduction
9.2. Live Attenuated Vaccine
9.2.1. Intramuscular Administration
9.2.2. Intranasal Administration
9.3. Monoclonal Antibody
9.3.1. Newer Generation Antibodies
9.3.2. Palivizumab
9.4. Subunit Vaccine
9.4.1. Peptide-based Vaccine
9.4.2. Protein-based Vaccine
10. Respiratory Syncytial Virus Vaccine for Children Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Private Hospitals
10.2.2. Public Hospitals
10.3. Online Providers
10.3.1. Direct Sale Websites
10.3.2. E-commerce Platforms
10.4. Retail Pharmacies
10.4.1. Independent Pharmacies
10.4.2. Supermarket Pharmacies
11. Respiratory Syncytial Virus Vaccine for Children Market, by Type of Manufacturer
11.1. Introduction
11.2. Big Pharmaceutical Companies
11.2.1. Established RSV Vaccines Makers
11.2.2. Potential Entrants in RSV Market
11.3. Biotech Firms
11.3.1. Established Biotech Firms
11.3.2. Start-ups
11.4. Generic Drug Manufacturers
11.4.1. International Players
11.4.2. Local Players
12. Respiratory Syncytial Virus Vaccine for Children Market, by Mode of Action
12.1. Introduction
12.2. Prophylactic
12.2.1. Preventive Antibodies
12.2.2. Preventive Vaccines
12.3. Therapeutic
12.3.1. Therapeutic Monoclonal Antibodies
12.3.2. Therapeutic Vaccines
13. Americas Respiratory Syncytial Virus Vaccine for Children Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Respiratory Syncytial Virus Vaccine for Children Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. AstraZeneca plc
16.3.3. Bavarian Nordic A/S
16.3.4. BiondVax Pharmaceuticals Ltd.
16.3.5. BioPharms Inc.
16.3.6. Clarus Therapeutics, Inc.
16.3.7. GlaxoSmithKline plc
16.3.8. GSK Biologicals SA
16.3.9. Johnson & Johnson (Janssen Pharmaceuticals)
16.3.10. Johnson Matthey Fine Chemicals
16.3.11. MedImmune, LLC (AstraZeneca)
16.3.12. Merck & Co., Inc.
16.3.13. Moderna Inc.
16.3.14. Novavax, Inc.
16.3.15. Pfizer Inc.
16.3.16. ReViral Ltd.
16.3.17. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET MULTI-CURRENCY
FIGURE 2. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET MULTI-LANGUAGE
FIGURE 3. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY FULL-TERM INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PREMATURE INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY CHILDREN WITH ASTHMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HEALTHY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HEALTHY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY IMMUNOCOMPROMISED CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INTRAMUSCULAR ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INTRANASAL ADMINISTRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY NEWER GENERATION ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PALIVIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PEPTIDE-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROTEIN-BASED VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DIRECT SALE WEBSITES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ESTABLISHED RSV VACCINES MAKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY POTENTIAL ENTRANTS IN RSV MARKET, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ESTABLISHED BIOTECH FIRMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY START-UPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY INTERNATIONAL PLAYERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LOCAL PLAYERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PREVENTIVE ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 125. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 127. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 128. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 129. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 130. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 131. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 132. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 133. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 135. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 136. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 137. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 138. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 139. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 140. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 141. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 142. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 143. CANADA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 144. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 146. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 147. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 148. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 149. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 150. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 151. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 152. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 154. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 155. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 156. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 157. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 158. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 161. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 162. MEXICO RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 163. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 165. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 166. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 167. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 168. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 169. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 170. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 171. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 173. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 174. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 175. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 183. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 185. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 186. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 187. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 188. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 189. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 190. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 191. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 194. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 196. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 203. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 204. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 205. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 206. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 207. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 208. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 209. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 210. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 211. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 213. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 214. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 215. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 216. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 217. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 222. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 224. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 225. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 226. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 227. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 228. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 229. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 230. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 232. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 233. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 234. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 235. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 236. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 237. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, 2018-2030 (USD MILLION)
TABLE 238. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
TABLE 239. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY PROPHYLACTIC, 2018-2030 (USD MILLION)
TABLE 240. CHINA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
TABLE 241. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 242. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 0 TO 6 MONTHS, 2018-2030 (USD MILLION)
TABLE 243. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 1 TO 5 YEARS, 2018-2030 (USD MILLION)
TABLE 244. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY 6 TO 12 MONTHS, 2018-2030 (USD MILLION)
TABLE 245. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF VACCINE, 2018-2030 (USD MILLION)
TABLE 246. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY LIVE ATTENUATED VACCINE, 2018-2030 (USD MILLION)
TABLE 247. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2030 (USD MILLION)
TABLE 248. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY SUBUNIT VACCINE, 2018-2030 (USD MILLION)
TABLE 249. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 251. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY ONLINE PROVIDERS, 2018-2030 (USD MILLION)
TABLE 252. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY RETAIL PHARMACIES, 2018-2030 (USD MILLION)
TABLE 253. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY TYPE OF MANUFACTURER, 2018-2030 (USD MILLION)
TABLE 254. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIG PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 255. INDIA RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR CHILDREN MARKET SIZE, BY BIOTECH FIRMS, 2018-2030 (USD MILLION)
TABLE 256. INDIA RESPIRATORY SYNCYTIAL VIR

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • BiondVax Pharmaceuticals Ltd.
  • BioPharms Inc.
  • Clarus Therapeutics, Inc.
  • GlaxoSmithKline plc
  • GSK Biologicals SA
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Johnson Matthey Fine Chemicals
  • MedImmune, LLC (AstraZeneca)
  • Merck & Co., Inc.
  • Moderna Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • ReViral Ltd.
  • Sanofi S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2025 - Product Image

Respiratory Syncytial Virus (RSV)- Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
Respiratory Syncytial Virus Vaccine for the Elderly Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Respiratory Syncytial Virus Vaccine for the Elderly Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global, United States Global, United States
From
Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Respiratory Syncytial Virus (RSV) Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Respiratory Syncytial Virus (RSV) Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Respiratory Syncytial Virus (RSV) Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.